AVIR
Price
$3.09
Change
-$0.05 (-1.59%)
Updated
Feb 21 closing price
Capitalization
265.21M
10 days until earnings call
PGEN
Price
$1.91
Change
-$0.06 (-3.05%)
Updated
Feb 21 closing price
Capitalization
554.99M
4 days until earnings call
Ad is loading...

AVIR vs PGEN

Header iconAVIR vs PGEN Comparison
Open Charts AVIR vs PGENBanner chart's image
Atea Pharmaceuticals
Price$3.09
Change-$0.05 (-1.59%)
Volume$309.14K
Capitalization265.21M
Precigen
Price$1.91
Change-$0.06 (-3.05%)
Volume$1.13M
Capitalization554.99M
AVIR vs PGEN Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. PGEN commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and PGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (AVIR: $3.14 vs. PGEN: $1.97)
Brand notoriety: AVIR and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 41% vs. PGEN: 76%
Market capitalization -- AVIR: $265.21M vs. PGEN: $554.99M
AVIR [@Biotechnology] is valued at $265.21M. PGEN’s [@Biotechnology] market capitalization is $554.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both AVIR and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 4 bearish.
  • PGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than AVIR.

Price Growth

AVIR (@Biotechnology) experienced а +0.96% price change this week, while PGEN (@Biotechnology) price change was -0.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

AVIR is expected to report earnings on May 07, 2025.

PGEN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($555M) has a higher market cap than AVIR($265M). PGEN YTD gains are higher at: 75.893 vs. AVIR (-6.269). PGEN has higher annual earnings (EBITDA): -136.11M vs. AVIR (-200.08M). AVIR has more cash in the bank: 483M vs. PGEN (28.6M). AVIR has less debt than PGEN: AVIR (1.84M) vs PGEN (5.75M). PGEN has higher revenues than AVIR: PGEN (3.96M) vs AVIR (0).
AVIRPGENAVIR / PGEN
Capitalization265M555M48%
EBITDA-200.08M-136.11M147%
Gain YTD-6.26975.893-8%
P/E RatioN/AN/A-
Revenue03.96M-
Total Cash483M28.6M1,689%
Total Debt1.84M5.75M32%
FUNDAMENTALS RATINGS
AVIR vs PGEN: Fundamental Ratings
AVIR
PGEN
OUTLOOK RATING
1..100
326
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8035
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (43) in the Biotechnology industry is in the same range as PGEN (73) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

AVIR's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

AVIR's SMR Rating (95) in the Biotechnology industry is in the same range as PGEN (98) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (35) in the null industry is somewhat better than the same rating for AVIR (80) in the Biotechnology industry. This means that PGEN’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (94) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRPGEN
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 18 days ago
78%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 20 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GDEUX23.58N/A
N/A
Goldman Sachs U.S. Equity ESG R6
LLINX15.65N/A
N/A
Longleaf Partners International
JFGAX10.42N/A
N/A
JHancock Fundamental Global Fran A
STEYX13.85N/A
N/A
AB International Strat Eqs Adv
ACFNX74.01N/A
N/A
American Century Focused Dynamic Gr R6

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with HEPA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then HEPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+1.62%
HEPA - AVIR
47%
Loosely correlated
+8.36%
MGTX - AVIR
46%
Loosely correlated
-0.87%
AXON - AVIR
46%
Loosely correlated
-8.70%
FHTX - AVIR
45%
Loosely correlated
-8.35%
RCKT - AVIR
45%
Loosely correlated
-0.46%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with RCKT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-2.96%
RCKT - PGEN
43%
Loosely correlated
-0.46%
NKTX - PGEN
42%
Loosely correlated
-6.11%
ALEC - PGEN
41%
Loosely correlated
+1.64%
AVIR - PGEN
40%
Loosely correlated
+1.62%
IDYA - PGEN
40%
Loosely correlated
+5.18%
More